What new treatments for Small Bowel Cancer are being developed in 2026

New Treatments for Small Bowel Cancer in Development

I appreciate your question about emerging treatments for small bowel cancer (SBA). Based on the most current medical guidelines available to me, I need to be transparent about what I can tell you:

What We Know from Current Guidelines

According to the NCCN Guidelines Version 4.2025 for Small Bowel Adenocarcinoma (the most recent available), several treatment approaches are actively being studied and refined:

Targeted Therapies Based on Genetic Mutations

The guidelines emphasize that SBA has a distinct genetic profile compared to colorectal cancer, which is opening new treatment possibilities:

• KRAS-targeted drugs: Since KRAS mutations are present in the vast majority of SBA cases, researchers are developing new inhibitors. The guidelines note that while KRAS G12C mutations occur in only ~1% of SBA cases, broader pan-RAS inhibitors are being explored.

• HER2-directed therapies: The NCCN Guidelines highlight that HER2 alterations are more common in SBA than in colorectal cancer, suggesting potential for HER2-targeted treatments.

• NTRK and RET gene fusions: Larotrectinib, entrectinib, repotrectinib (for NTRK fusions) and selpercatinib (for RET fusions) are recommended as options in subsequent lines of therapy.

Immunotherapy Advances

According to NCCN Guidelines, checkpoint inhibitors show promise, particularly for:

• dMMR/MSI-H tumors (deficient mismatch repair/microsatellite instability-high): Pembrolizumab, nivolumab ± ipilimumab, and dostarlimab-gxly
• TMB-H tumors (tumor mutational burden-high): Pembrolizumab as a category 2B option
• POLE/POLD1 mutations: Ultra-hypermutated phenotypes responding to checkpoint inhibitors

Chemotherapy Optimization

The guidelines recommend:

• FOLFOX, CAPEOX, FOLFIRINOX ± bevacizumab for first-line advanced disease
• Strategies to minimize oxaliplatin neurotoxicity (nerve damage) through treatment breaks

Important Limitations

I don't have specific information about treatments entering clinical trials in 2026 because:

1. My guidelines are current through October 2025
2. New drug development timelines extend beyond what's documented in current guidelines
3. Clinical trial announcements typically come closer to their launch dates

What You Should Do

To learn about the newest 2026 developments, I recommend:

1. Ask your oncologist directly: "What new clinical trials are opening in 2026 that might be relevant to my tumor's genetic profile?"

2. Check these resources regularly:

   • ClinicalTrials.gov - Search "small bowel cancer" and filter by "recruiting" status
   • NCCN Guidelines (nccn.org) - Updated quarterly
   • American Cancer Society - Maintains current treatment information
   • Cancer Commons - Offers free second opinions and trial matching

3. Genetic testing is critical: According to NCCN Guidelines, molecular profiling of your tumor should identify specific mutations that may qualify you for targeted therapy trials.

Questions to Ask Your Care Team

1. "Has my tumor been tested for KRAS, HER2, NTRK, RET, dMMR/MSI-H, and TMB status?"
2. "Are there any clinical trials opening in 2026 that match my tumor's genetic profile?"
3. "What new targeted or immunotherapy options might become available for my specific mutation status?"
4. "Should I consider getting a second opinion at a high-volume cancer center about emerging treatment options?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about your specific treatment plan.